Study finds significantly lower rates of provider-initiated exome reanalysis among diverse racial, ethnic, and ancestral groups highlighting the importance of proactive reanalysis offerings like Ambry ...
SALT LAKE CITY, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc (MYGN). (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it will unveil groundbreaking ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback